News headlines about OraSure Technologies (NASDAQ:OSUR) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OraSure Technologies earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 47.3736978427358 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have effected Accern’s rankings:

OSUR has been the subject of a number of research reports. Jefferies Group LLC upped their price objective on OraSure Technologies from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 4th. Canaccord Genuity upped their price objective on OraSure Technologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday. Zacks Investment Research cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, April 12th. BidaskClub cut OraSure Technologies from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Stephens reiterated an “overweight” rating and issued a $19.00 price objective (up from $14.00) on shares of OraSure Technologies in a report on Tuesday, July 11th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $15.46.

OraSure Technologies (NASDAQ:OSUR) last issued its earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.02. OraSure Technologies had a return on equity of 15.64% and a net margin of 22.29%. The firm had revenue of $40.18 million for the quarter, compared to analysts’ expectations of $36.54 million. During the same period in the previous year, the firm posted $0.07 earnings per share. The business’s revenue was up 28.1% compared to the same quarter last year.

In other news, EVP Anthony Zezzo II sold 115,000 shares of OraSure Technologies stock in a transaction dated Wednesday, May 10th. The stock was sold at an average price of $14.70, for a total value of $1,690,500.00. Following the sale, the executive vice president now directly owns 260,410 shares of the company’s stock, valued at $3,828,027. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Douglas A. Michels sold 209,800 shares of OraSure Technologies stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $15.01, for a total value of $3,149,098.00. Following the completion of the sale, the chief executive officer now directly owns 782,025 shares in the company, valued at $11,738,195.25. The disclosure for this sale can be found here. Insiders sold 704,979 shares of company stock worth $11,031,816 over the last ninety days. Insiders own 7.80% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect OraSure Technologies (NASDAQ:OSUR) Stock Price” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/07/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-orasure-technologies-nasdaqosur-stock-price.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Insider Buying and Selling by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.